Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis

• Published in: The Journal of clinical investigation 2016-06, Vol.126 (6), p.2236-2248
• Main Authors: Winnick, Jason J, Kraft, Guillaume, Gregory, Justin M, Edgerton, Dale S, Williams, Phillip, Hajizadeh, Ian A, Kamal, Maahum Z, Smith, Marta, Farmer, Ben, Scott, Melanie, Neal, Doss, Donahue, E Patrick, Allen, Eric, Cherrington, Alan D
• Format: Article
• Language: English
• Subjects: Animals; Biomedical research; Biopsy; Blood Glucose - metabolism; Brain - metabolism; Development and progression; Diabetes Mellitus, Type 1 - metabolism; Disease Models, Animal; Dogs; Female; Fructose - administration & dosage; Glucose; Glucose - metabolism; Glucose Clamp Technique; Glycerol; Glycogen; Growth hormones; Health aspects; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemia - blood; Hypoglycemia - metabolism; Insulin; Insulin - metabolism; Laboratory animals; Lactic Acid - metabolism; Lipid Metabolism; Liver; Liver - metabolism; Liver Glycogen - metabolism; Male; Physiological aspects; Rodents; Signal Transduction; Software; Type 1 diabetes
• ISSN: 0021-9738; 1558-8238
• DOI: 10.1172/JCI79895

Liver glycogen is important for the counterregulation of hypoglycemia and is reduced in individuals with type 1 diabetes (T1D). Here, we examined the effect of varying hepatic glycogen content on the counterregulatory response to low blood sugar in dogs. During the first 4 hours of each study, hepatic glycogen was increased by augmenting hepatic glucose uptake using hyperglycemia and a low-dose intraportal fructose infusion. After hepatic glycogen levels were increased, animals underwent a 2-hour control period with no fructose infusion followed by a 2-hour hyperinsulinemic/hypoglycemic clamp. Compared with control treatment, fructose infusion caused a large increase in liver glycogen that markedly elevated the response of epinephrine and glucagon to a given hypoglycemia and increased net hepatic glucose output (NHGO). Moreover, prior denervation of the liver abolished the improved counterregulatory responses that resulted from increased liver glycogen content. When hepatic glycogen content was lowered, glucagon and NHGO responses to insulin-induced hypoglycemia were reduced. We conclude that there is a liver-brain counterregulatory axis that is responsive to liver glycogen content. It remains to be determined whether the risk of iatrogenic hypoglycemia in T1D humans could be lessened by targeting metabolic pathway(s) associated with hepatic glycogen repletion.